Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | VHL | P40337 | 2/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705544 | 0.85 | ATM (0.41) | ATMMMP2ANPEPALDH1A1FKBP1A | |
| SCHEMBL13920516 | 0.85 | ATM (0.41) | ATMMMP2ANPEPALDH1A1FKBP1A | |
| SCHEMBL13409006 | 0.82 | MMP2 (0.44) | ATMMMP2ANPEPALDH1A1FKBP1A | |
| SCHEMBL25109725 | 0.81 | FKBP1A (0.39) | ATMALDH1A1VHLFKBP1AKMT2A | |
| SCHEMBL3783080 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL | |
| SCHEMBL10793356 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL | |
| SCHEMBL3783083 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL | |
| SCHEMBL3784082 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL | |
| SCHEMBL3789111 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL | |
| SCHEMBL3788774 | 0.81 | MMP2 (0.72) | ATMMMP2ANPEPALDH1A1VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3932638-A | Compositions and methods for wound healing | FRANCO-CHIMIE S.A.R.L. (FR) | 1976-01-13 | — | — | US | claimed |
| US-20090118353-A1 | Medicinal composition | KITAJIMA AKIHIKO | 2009-05-07 | — | — | US | disclosed |
| US-7485665-B2 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20050239861-A1 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1547593-A1 | MEDICINAL COMPOSITION | Nagase Chemtex Corporation (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-0864563-B1 | N-Acyl-hydroxy amino acid esters used to protect skin and hair | HAARMANN & REIMER GMBH (DE) | 2002-10-02 | — | — | EP | disclosed |
| US-3997559-A | N-acetyl-L-hydroxy-proline zinc salt | FRANCO CHIMIE S.A.R.L. (FR) | 1976-12-14 | — | — | US | disclosed |
| US-3932638-A | Compositions and methods for wound healing | FRANCO-CHIMIE S.A.R.L. (FR) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239861-A1 | Medicinal composition | HTR4, HTR2C, HTR1A | ATM 4070/4885MMP2 160/4885ANPEP 1122/4885 |
| US-20090118353-A1 | Medicinal composition | HTR4, FABP2, SLC10A2 | ATM 3644/4885MMP2 117/4885ANPEP 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.